Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer

Journal of Nuclear Medicine

Volumn 38, Issue 12, 1997, Pages 1907-1911

  Minn, Heikki ^a   Lapela, Maria ^b   Klemi, Pekka J ^b   Grénman, Reidar ^b   Leskinen, Sirkku ^b   Lindholm, Paula ^b   Bergman, Jörgen ^b   Eronen, Esa ^b   Haaparanta, Merja ^b   Joensuu, Heikki ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b NONE

Author keywords

Head neoplasms; Neck neoplasms; PET; Survival; Tumor grading

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MITOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031445833     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adams GL. Treatment of head and neck cancer with combined modalities. Invest Radiol 1989;24:562-567.
2. Sturgis EM, Weiner RS, Miller RH. Laryngeal preservation. J La State Med Soc 1995;147:9-15.
3. Corvò R, Giaretti W, Sanguineti G, et al. Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. Int J Radiat Oncol Biol Phys 1993;27:1165-1172.
4. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584.
5. Klijanienko J, El-Naggar AK, de Braud F, et al. Tumor vascularization, mitotic index, histopathologic grade and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 1995;75:1649-1656.
6. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-3058.
7. Braams JW, Pruim J, Freling NJM, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211-216.
8. McGuirt WF, Williams DW, Keyes JW, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995;105:373-375.
9. Haberkorn U, Strauss L, Reisser Ch, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-1555.
10. 18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-371.
11. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992;182:185-194.
12. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-329.
13. Hermanek P, Sobin LH, eds. UICC TNM classification of malignant tumors, 4th ed. Berlin: Springer-Verlag; 1992.
14. Rowell NP, McCready VR, Tait D, et al. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumors. Br J Cancer 1989;59:135-141.
15. 18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
16. Minn H, Leskinen-Kallio S, Lindholm P, et al. Fluorine-18-fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomog 1993;17:115-123.
17. Zasadny K, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.
18. Minn H, Zasadny KR, Quint LE, Wahl RL, Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-173.
19. Klemi P-J, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in epithelial ovarian carcinoma. Cancer 1995;76:1201-1208.
20. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
21. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transport messenger RNA are induced by ras or src oncogenes. Science 1987;235: 1492-1494.
22. Burk DM, Woods M, Hunter J. On the significance of glucolysis for cancer growth with special reference to Morris rat hepatomas. J Natl Cancer Inst 1967;38:839-863.
23. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992;11:445-456.
24. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Cancer 1988;61:1776-1781.
25. Kapoor RR, Spence AM, Muzi M, et al. Determination of the deoxyglucose and glucose phosphorylation ratio and the lumped constant in rat brain and a transplantable rat glioma. J Neurochem 1989;53:37-44.
26. Lapela M, Grénman R, Kurki T, et al. Head and neck cancer: detection of recurrence with positron emission tomography and 2-[fluorine-18]fluoro-2-deoxy-D-glucose. Radiology 1995;197:205-211.
27. Keyes JW Jr, Harkness BA, Greven KM, Williams DW, Watson NE, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET. Radiology 1994;192:99-102.
28. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.